Lower extremity peripheral arterial disease (PAD) affects 18% of men and women ≥55 years of age in general medical practices. 1 PAD is associated with a 5- to 6-fold increased risk of cardiovascular ...

Semaglutide was associated with improved maximum walking distance across type 2 diabetes subgroups among patients with ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

A post-hoc analysis of STRIDE confirms the benefit of GLP-1 RA in patients with peripheral arterial disease and type 2 ...

Global Peripheral Artery Disease Market is valued at approximately USD 4.5 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.7% over the forecast period 2024-2032.

A “slow developing” symptom in the feet could be a warning sign of high cholesterol and even heart disease. This lesser-known ...

Semaglutide 1 mg improves walking distance in patients with early peripheral artery disease and type 2 diabetes, regardless ...

A new statement from leading heart and blood vessel experts in Europe is providing clinical guidance for treatments to ...

A new statement from leading heart and blood vessel experts in Europe is providing clinical guidance for treatments to ...

Polyvascular disease, defined as the presence of atherosclerotic disease involving ≥2 vascular beds (coronary, peripheral, or cerebrovascular), is common among patients with PAD and has recently ...